You are here
Cannabix Technologies Comments on Legalization of Marijuana in Canada, Impaired Driving and Workplace Safety
The Cannabix Marijuana Breathalyzer is being developed to give law enforcement and employers a tool to enforce public safety.
VANCOUVER, British Columbia, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace provides the following statement related to the legalization of marijuana for recreational use across Canada: “The introduction of legalized marijuana use in Canada is a watershed moment as it relates to public safety on our roads and workplaces. Cannabix applauds the significant efforts that are underway by the Government of Canada and others to increase public awareness of the dangers of drugged driving on our roadways and the acute problems of being under the influence of drugs in the workplace. A recent survey by the Angus Reid Institute (dated September 25, 2018) finds a majority of Canadians lack confidence in the ability of their community police to assess and punish those driving under the influence of marijuana. Furthermore, according to MADD Canada, drugs are present in fatal crashes nearly twice as often as alcohol and that Canada’s existing system does a very poor job of detecting drivers under the influence of drugs (news release May 29, 2018). The Human Resources Professionals Association in January 2018, conducted a survey in Ontario and found that 71 per cent of its members do not feel prepared for legalization, with almost 48 per cent citing concerns about ensuring a safe workplace. As the issue of drugged driving and influence of drugs in the workplace becomes increasingly acute, Cannabix is using its technology, research and development (R&D) and scientific experience to develop effective tools to aid law enforcement and help governments and the public transition to marijuana legalization in various jurisdictions. Cannabix Technologies has been on the forefront in R&D to create an accurate breath test for ∆9-tetrahydrocannabinol - the psychoactive component of marijuana that causes impairment. We believe that establishing point-of-care breath testing technology for cannabis is the future for law enforcement and workplace testing, as it is non-invasive, will be easy to use, and will look to provide superior sensitivity to help better determine impairment. Cannabix is a well funded Canadian company that is rapidly developing marijuana breathalyzer technology.
Cannabix has been building upon its promising characterization results from August and with a secondary bench version device to establish repeatable results in multiple devices. Thus far testing has demonstrated the ability to isolate ∆9-tetrahydrocannabinol (“THC”) and suppress background substrates and scientists are continuously working to improve resolving power. Cannabix is developing an innovative FAIMS (field asymmetric waveform ion mobility spectrometry) based instrument for the detection of THC.
FAIMS works as an “ion blocking” technology, essentially blocking unwanted ions/analytes and allowing specified ions to pass through for detection. The characterization work has been conducted using a bench version of the FAIMS device. Cannabix scientists have been actively tuning the FAIMS device coupled to real time switchable mass spectrometry to detect key molecules and their complex pathways in the body to enable the identification of recency of use.
The Company also reports that it has short listed 2 potential medical device development companies in order to develop the next version of the device as well as create multiple devices, that would be used for pilot testing.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a leader in marijuana breathalyzer development for law enforcement and the workplace. Cannabix has established breath testing technologies in the pursuit of bringing durable, portable hand-held tools to market to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in many global jurisdictions. Cannabix is working to develop drug-testing devices that will detect THC- the psychoactive component of marijuana that causes intoxication- using breath samples. In particular, Cannabix is focused on developing breath testing devices for detection of recent use of THC, in contrast to urine testing for THC metabolite that requires an invasive collection and reflects usage, days or even weeks earlier. The devices will also be useful for other practical applications such as testing employees in the workplace where impairment by THC can be hazardous.
We seek Safe Harbor.
On behalf of the Board of Directors
Cannabix Technologies Inc.
For further information, contact the Company at firstname.lastname@example.org
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (iv) the ability of the Company to develop and market its future product; and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing “patent pending” technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.